Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive
Conditions
Brief summary
This is a single-arm, open-label, dose escalation, phase I study, aiming to evaluate the safety and efficacy of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific Chimeric Antigen Receptor (CAR) T-cells in patient with relapsed or refractory diffuse B cell lymphoma.
Detailed description
CD19 CAR-T cell therapy has made breakthroughs in the treatment of B cell lymphoma and leukemia, but 30% of patients still have antigen escape, which may be related to variants in tumor cells and the expansion of CD19-negative tumor cells after treatment with CD19 CAR-T cells. CD19/CD20 bispecific CAR-T cell targeting multiple antigens can attack tumor cells while overcoming tumor antigen escape caused by a single target, maximizing efficacy and duration of treatment, and can also solve the problem of uneven distribution or low expression of single target on the tumor surface.
Interventions
Humanized anti-CD19 and CD20 bispecific autologous CAR-T cells injection: the first dose is 1.0×106 /kg, the second dose is 3.0×106 /kg, and the third dose is 8.0×106 /kg. Patients will receive lymphodepleting chemotherapy at least 1 week before CAR-T cell infusion.
Sponsors
Fujian Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. The subject or her/his legally guardian(s) must sign the informed consent form approved by the Institutional Ethics Committee (IEC) prior to any screening procedures; 2. Subjects aged 18 years or older with relapsed or refractory DLBCL (primary mediastinal large B-cell lymphoma and transformed follicular lymphoma included), of which refractory is defined as: Have no response to the recent treatment including: * The best response to the treatment regimen is progressive disease (PD) ,or * stable disease (SD) which maintained less than 6 months after the last treatment, or * not suitable for autologous hematopoietic stem cell transplantation (ASCT), or ASCT refractory, including: * progressive disease after ASCT or relapse within 12 months (relapse must be confirmed by biopsy), or * If remedial treatment is given after ASCT, the subject must have no response or relapse after the last treatment. 3. Subjects who have previously received ≥2 lines treatment, and at least including: * Anti-CD20 monoclonal antibody(rituximab), unless the CD20 negative; * A chemotherapy regimen containing anthracyclines; * The DLBCL patients who transformed from follicular lymphoma must have previously received chemotherapy for follicular lymphoma and have developed chemotherapy-refractory diseases after transform to DLBCL. 4. Confirmation for either CD19 or CD20 positivity using immunohistochemistry or flow cytometry; 5. According to the initial evaluation, staging and response assessment of Hodgkin's and non-Hodgkin's lymphoma -the Lugano Classification (2014), there is at least one measurable lesion at baseline; 6. Life expectancy ≥12 weeks; 7. Eastern Cooperative Oncology Group (ECOG) performance status that is either 0 or 1 at screening; 8. Adequate organ function: Renal function defined as: * A serum creatinine of ≤1.5 × Upper Limit of Normal (ULN), or; * Estimated Glomerular Filtration Rate (eGFR) ≥60 ml/min/1.73m2； Liver function defined as: * ALT≤ 5 × Upper Limit of Normal (ULN) for age, and; * Total bilirubin ≤ 2.0 mg/dl with the exception of patients with Gilbert-Meulengracht syndrome; patients with Gilbert-Meulengracht syndrome may be included if their total bilirubin is ≤ 3.0 × ULN and direct bilirubin ≤ 1.5 × ULN. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and blood oxygen saturation \> 91% on room air; 9. Hemodynamically stable and Left Ventricle Ejection Fraction (LVEF) ≥ 45% confirmed by echocardiogram or Multigated Radionuclide Angiography (MUGA); 10. Adequate bone marrow reserve without transfusions defined as: * Absolute neutrophil count (ANC) \>1×10\^9 /L； * Absolute lymphocyte count (ALC) ≥0.3×10\^9 /L； * Platelets ≥50×10\^9 /L; * Hemoglobin \> 8.0 g/dl; 11. Must have an apheresis product of non-mobilized cells or peripheral blood harvested cells accepted for manufacturing 12. Subjects who use the following drugs should meet the following criteria: * Steroids: Therapeutic doses of steroids must be stopped 2 weeks prior to A-02 infusion. However, the following physiological replacement doses of steroids are allowed: \< 6 - 12 mg/m\^2/day hydrocortisone or equivalent; * Immunosuppression: Any immunosuppressive medication must be stopped ≥ 4 weeks prior to sign the informed consent form; * Anti-proliferative therapy other than pretreatment chemotherapy within 2 weeks of A-02 infusion; * CD20 antibody-related treatment must be discontinued within 4 weeks of A-02 infusion or 5 half-lives (whichever is longer); * CNS disease prophylaxis must be stopped \> 1 week prior to A-02 infusion (e.g. intrathecal methotrexate); 13. The investigator judged that the subject recovered from the toxicity of the previous anti-tumor treatment to grade 1 or below (except for special grade 2 or below toxicity that cannot be recovered in a short period of time, such as hair loss), suitable for pretreatment. Chemotherapy and treatment of CAR-T cells; 14. Women of child-bearing potential and all male subjects must agree to use highly effective methods of contraception for at least 12 months following A-02 infusion and until CAR-T cells are no longer present by PCR on two consecutive tests.
Exclusion criteria
1. Prior treatment with any cell therapy before signing the informed consent form, including CAR-T therapy; 2. Subjects with detectable cerebrospinal fluid malignant cells or brain metastases, or with a history of central nervous system (CNS) lymphoma or primary CNS lymphoma; 3. Subjects with testicular invasion, including those who have had testicular resection; 4. Subjects with current or previous history of central nervous system disease, such as seizures, cerebral ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease involving the central nervous system; 5. Subjects who have previously received allogeneic hematopoietic stem cell transplantation (HSCT); or suitable and consenting to Autologous hematopoietic stem cell transplantation (ASCT); 6. Chemotherapy other than lymphodepleting chemotherapy within 2 weeks of A-02 infusion; 7. Patients on oral anticoagulation therapy within 1 week of A-02 infusion; 8. Prior radiation therapy within 2 weeks of A-02 infusion; 9. Investigational medicinal product within the last 30 days prior to sign the informed consent form; 10. Subjects with active hepatitis B（defined as hepatitis B surface antigen positive, or hepatitis B core antibody positive with hepatitis B virus DNA detection value \> 1000 copies/ml）or hepatitis C (HCV RNA positive) 11. Subjects positive for HIV antibody or treponema pallidum antibody; 12. Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive ≤ 72 hours prior to A-02 infusion) 13. Unstable angina and/or myocardial infarction within 6 months prior to sign the informed consent form; 14. Previous or concurrent malignancy with the following exceptions: * Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to sign the informed consent form); * In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to sign the informed consent form; * A primary malignancy which has been completely resected and in complete remission for ≥ 5 years; 15. Pregnant or nursing women (women of childbearing age were tested positive for pregnancy during screening period); 16. Cardiac arrhythmia not controlled with medical management; 17. Subjects with active neurological auto immune or inflammatory disorders (e.g. Guillain Barre Syndrome, Amyotrophic Lateral Sclerosis); 18. Other conditions that the investigator thinks he/she should not be included in this clinical trial, such as poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The types and Incidence of adverse events | Up to 12 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate | Up to 12 months | including CR and PR |
| Progression-free survival (PFS) | Up to 12 months | — |
| Response duration | Up to 12 months | — |
Countries
China
Contacts
Primary ContactJianda Hu, Prof.M.D.Ph.D
Outcome results
None listed